Current standards and future perspectives in adjuvant treatment for biliary tract cancers
Three phase III trials have been recently published exploring the role of adjuvant chemotherapy in resected cholangiocarcinoma and gallbladder cancer. The trials differ in some of the baseline characteristics which may explain why only the BILCAP trial (capecitabine vs observation) was the only study showing benefit in favour of adjuvant chemotherapy in resected biliary tract cancer. Panel A shows main differences in study characteristics. Panel B provides a graphic representation of HR for Relapse-free and Overall survival, with further details summarised in Panel C.
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Angela Lamarca, Julien Edeline, Mair éad G McNamara, Richard A Hubner, Masato Nagino, John Bridgewater, John Primrose, Juan W Valle Tags: Anti-Tumour Treatment Source Type: research
More News: Bile Duct Cancer | Cancer | Cancer & Oncology | Chemotherapy | Cholangiocarcinoma | Gallbladder Cancer | Study | Xeloda